Physician profile
David D Chism
NPI 1972805414
$45,443.07
in general payments reported to CMS, 2019-2025
46 companies · $2,623 in 2025
The $2,623 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.77 · 2020: $1,992 · 2021: $2,762 · 2022: $7,203 · 2023: $24K · 2024: $6,442 · 2025: $2,623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $27K · Food and Beverage: $2,827 · Travel and Lodging: $1,844 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $27,058.00 |
| Food and Beverage | $2,826.71 |
| Travel and Lodging | $1,844.37 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,725.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $11,320.64 | 2023 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $9,517.93 | 2023-2025 | Enhertu, Lynparza, Tagrisso |
| Exelixis INC. | $7,137.33 | 2019-2022 | |
| Pfizer INC. | $4,898.78 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $3,455.25 | 2024-2025 | Opdivo |
| Genentech USA, INC. | $1,941.48 | 2022-2025 | Venclexta |
| Cti Biopharma Corp. | $1,725.00 | 2023 | Vonjo |
| Aveo Pharmaceuticals, INC. | $1,542.67 | 2021-2025 | |
| Seagen INC. | $1,250.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $966.18 | 2025 | |
| Novartis Pharmaceuticals Corporation | $190.74 | 2019-2025 | |
| Glaxosmithkline, LLC. | $139.87 | 2025 | Ojjaara, Blenrep, Zejula |
| Pharmacosmos Therapeutics INC. | $136.74 | 2024-2025 | Cosela, Monoferric |
| Gilead Sciences, INC. | $109.16 | 2021-2025 | Trodelvy |
| Tempus Ai, INC | $107.66 | 2024 | Xt Cdx |
Show all 40 companies
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Chism listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.